Blake Buzard

Saint Luke's Hospital

Papers

1

Total Citations

9

H-Index

1

About

Blake Buzard is a clinician-researcher whose work sits at the intersection of precision oncology and minimally invasive surgical innovation. His most cited study, a 2023 case report, documents the first known response to the targeted therapy osimertinib in a colorectal cancer patient harboring an *EGFR* T790M mutation—a finding that challenges conventional tissue-specific treatment paradigms and opens new avenues for mutation-driven therapy in gastrointestinal malignancies. This work, which has already garnered 9 citations, highlights Buzard’s focus on translating molecular insights into actionable clinical strategies. Beyond oncology, Buzard is deeply engaged in advancing minimally invasive surgical techniques, particularly in complex procedures like oesophagectomy. He advocates for the laparoscopic, thoracoscopic, and robotic approaches, emphasizing that improved visualization and ergonomics can flatten the steep learning curve of these operations, ultimately expanding patient access to less invasive care. His contributions bridge the gap between targeted therapeutics and surgical innovation, making him a notable voice in the evolving landscape of multidisciplinary cancer management.

Research Focus

Key Achievements

1
H-Index
1
Papers
9
Total Citations
9
Avg Citations/Paper
🏆 Most Cited Paper
Response to osimertinib in a colorectal cancer patient with an <i>EGFR</i> T790M mutation: A case report
9 citations · 2023
📈 Most Prolific Year: 2023 (1 Papers)
🤝 Key Collaborators: 6
🏛 Institutions: Saint Luke's Hospital

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago